Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03974243

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Phase Ib/IIa Study of Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Sponsor: Chipscreen Biosciences, Ltd.

Conditions Non-hodgkin's Lymphoma

Interventions Chiauranib Chidamide

Updated 6 times since 2019 Last updated: Mar 7, 2022 Started: Jul 11, 2019 Primary completion: Dec 31, 2021 Completion: Dec 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03974243, this PHASE1/PHASE2 trial focuses on Non-hodgkin's Lymphoma and remains completed. Sponsored by Chipscreen Biosciences, Ltd., it has been updated 6 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2

Status: Recruiting → Completed
Sep 2021 — Apr 2022 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Sep 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2

▶ Show 1 earlier version

Jul 2019 — Jan 2021 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chipscreen Biosciences, Ltd.

Data source: Chipscreen Biosciences, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China